I had the opportunity to attend the postdoc lunch with Dr Antonio Omuro of @StanfordMed today, followed by his talk at @BrainTumorInst Seminar series.
Don’t have pictures from the lunch, but I left feeling motivated - in these troubling times, we must keep working hard!
#ICYMI MBTI's very own Priya Kumthekar, MD, Atique Ahmed, PhD, and Ditte Primdahl, MD, will be attending the 6th annual Glioblastoma Drug Development Summit. Dr. Kumthekar will host a roundtable, while Professor Ahmed and Dr. Primdahl will host workshops. https://t.co/rj6xyAKFTC
I wish I heard this George Church (@geochurch) podcast episode when I was a grad student! 1. You can change the world, as long as you don't care who gets credit. 2. The idea is not to never fail, it is to fail a million times a day. 3. Embrace the outlier!
We are pleased to host the first Day of Celebration for brain tumor patients, caregivers, loved ones, advocates, and ambassadors. Join us for a family-friendly social event!
Click the link for more info:
https://t.co/gsRKqMjxJm
Please join us for a day of celebration on Sunday, November 10, for brain tumor patients, their families, caregivers, advocates, and ambassadors. Enjoy music, games, food and connecting with other members of the brain tumor community.
https://t.co/0zJLy7ObrA
@NeurosurgeryNM@BrainTumorInst
Great participation at annual meeting with our medical students.
18 posters
6 oral presentations
2 awards
The next generation of future neurosurgeons is coming on strong!
#Glioblastoma is a highly aggressive and malignant #BrainTumor with limited therapeutic options and a poor prognosis. A promising alternative strategy is to harness the immune system's potential against tumor cells. Previous data showed that the B-cell-based vaccine can induce therapeutic responses in preclinical models of glioblastoma. This study, co-authored by @NorthwesternMed neurologists, aimed to characterize the antigenic reactivity of the vaccine’s antibodies and evaluate their therapeutic potential. Learn more:
https://t.co/kEdlRaTVwL #MedTwitter #NeuroTwitter
MBTI's Priya Kumthekar, MD recently led a national study of advanced #CSF analyses of patients with HER2+ #BreastCancer & leptomeningeal #metastases. Learn about this retrospective analysis & its implications for informing future therapies: https://t.co/jYyhzl6Csd. @LurieCancer